Prostate Cancer

Prostate cancer is the second most common form of cancer in men in the US with an estimated 175,000 new cases expected to be diagnosed in 2019. Approximately 77 percent of patients in the US are diagnosed with localized disease that has not progressed beyond the confines of the prostate. Research has shown that patients with early, localized disease have a low likelihood of the cancer spreading beyond the confines of the prostate; however, many men with clinically significant localized disease choose to undergo radical treatment. Radical therapies include surgery to remove the entire prostate and/or radiation. Potential toxicities from radical treatments can be significant and permanent and include erectile dysfunction, urinary incontinence, and rectal toxicity.

Understanding How Topsalysin Could Treat Both Localized Prostate Cancer and BPH